To effectively translate HF’s promising preclinical findings into clinical benefit, future development should focus on three strategic clinical positionings: (1) Given that HF’s cytotoxicity is notably higher in p53-wild-type cells compared to p53-null or mutant lines, future clinical trial designs should consider p53 status as a predictive biomarker. Here, TP53 is linked to hydrops fetalis.